Literature DB >> 15079187

[OK-432 therapy for lymphangioma in children].

Everaldo Ruiz1, Elvis T Valera, Francisco Veríssimo, Luiz G Tone.   

Abstract

OBJECTIVE: To report the experience with OK-432 therapy for lymphangioma in children.
METHODS: Retrospective study of 19 children with lymphangioma treated with OK-432 in Ribeirão Preto, state of São Paulo, Brazil, between 1999 and 2003.
RESULTS: All patients presented response to OK-432, 12 had total shrinkage and seven had partial shrinkage varying from 50 to 80%. Patients had fever after injections of OK-432 for 2 to 10 days, no damage to the overlying skin was observed.
CONCLUSION: OK- 432 is safe, effective and can be used as primary choice of treatment of patients with lymphangiomas because of the excellent response. In these cases surgery should not be necessary. In patients with partial regression new injections of OK-432 must be used to shrink the lesion. Thereby safely surgery could be made.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15079187     DOI: 10.2223/1156

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  6 in total

1.  Further experience with OK-432 for lymphangiomas.

Authors:  C Luzzatto; R Lo Piccolo; F Fascetti Leon; G F Zanon; T Toffolutti; A Tregnaghi
Journal:  Pediatr Surg Int       Date:  2005-10-25       Impact factor: 1.827

2.  Cross-sectional study comparing different therapeutic modalities for cystic lymphangiomas in children.

Authors:  Hugo de Oliveira Olímpio; Joaquim Bustorff-Silva; Antonio Gonçalves de Oliveira Filho; Kleber Cursino de Araujo
Journal:  Clinics (Sao Paulo)       Date:  2014-08       Impact factor: 2.365

3.  Retroperitoneal and genital lymphangioma therapeutic challenges in a developing country.

Authors:  Jk Olabanji; Ao Oladele; Oc Famurewa; O Adejuyigbe; Sa Ademola
Journal:  Libyan J Med       Date:  2009-03-01       Impact factor: 1.657

4.  Lymphangioma: Is intralesional bleomycin sclerotherapy effective?

Authors:  Z Rozman; R R Thambidorai; A M Zaleha; Z Zakaria; M A Zulfiqar
Journal:  Biomed Imaging Interv J       Date:  2011-07-01

Review 5.  Microorganisms in the Treatment of Cancer: Advantages and Limitations.

Authors:  Klaudia Łukasiewicz; Marek Fol
Journal:  J Immunol Res       Date:  2018-02-27       Impact factor: 4.818

6.  Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model.

Authors:  Xiaojin Li; Meng Qi; Kai He; Haiyan Liu; Wenlan Yan; Lizhuo Zhao; Yanyan Jia; Lei He; Chaochao Lv; Min Zhang; Zhiguo Wei; Wenchao Yan; Tianqi Wang; Fuchang Yu; Weifeng Qian
Journal:  Parasit Vectors       Date:  2022-09-23       Impact factor: 4.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.